Detecting Protein in the Brain Before and After Death

What we are studying

This is a research study for the investigational drug 18F-AV-1451 used as a brain imaging drug in positron emission tomography (PET). PET is a way to look at a picture of the inside of the body. The purpose of this study is to see how well 18F-AV-1451 works in the detection of protein deposits in the brain. 18F-AV-1451 sticks to a special type of protein in the brain called tau protein and can be seen in pictures taken using a PET/CT scanner. This protein has been linked to people who have dementia or Alzheimer’s disease or may develop Alzheimer’s disease. Pictures of the brain made using the study drug during the life of study participants will be compared to results of brain autopsy after death. Autopsy is the examination of the body or body parts after death.

Who is Eligible

  • Genders:
    • Men
    • Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 50+

Eligibility Criteria

  • Projected life expectancy of ? 6 months
  • Tolerate a 20 minute PET scan
  • Ability to provide consent or assent and/or have a LAR to consent for them

What is involved

  • 1 screening visit to determine eligibility
  • 1 visit to complete the PET scan
  • 1 follow-up phone call 2-3 days after PET scan
  • Optional 2nd PET scan 6 months after initial scan with follow up phone call 2-3 days later
  • Autopsy of brain upon participant death.


Screening $25, Baseline $75, Optional 6 Month PET Scan $75, Brian Autopsy $250 (will be paid to LAR)

Contact Information

Study Coordinator
Tim Collare
[email protected]
Principal Investigator
Kaycee Sink, MD

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.